Skip to Content

Join the 'Immune Globulin Subcutaneous' group to help and get support from people like you.

Immune Globulin Subcutaneous News

'Immunotherapy' in Monkeys Shows Promise as Long-Term HIV Treatment

Posted 13 Mar 2017 by Drugs.com

MONDAY, March 13, 2017 – Lab experiments with monkeys suggest that "immunotherapy" holds promise as a long-term treatment for HIV, researchers say. Treatment with two anti-HIV antibodies right after infection might help keep the AIDS-causing virus in check for a prolonged period, according to the new study. Despite an arsenal of HIV drugs, effective long-term treatment remains elusive because inactive versions of the virus lie in wait for an opportunity to attack the immune system, said the researchers from Rockefeller University in New York City and the U.S. National Institutes of Health. "This [new] form of therapy can induce potent immunity to HIV, allowing the host to control the infection," said Michel Nussenzweig, head of Rockefeller's laboratory of molecular immunology. "It works by taking advantage of the immune system's natural defenses, similar to what happens in some forms ... Read more

Related support groups: HIV Infection, Pre-Exposure Prophylaxis, Hizentra, RhoGAM, Gamunex, Diagnosis and Investigation, Gammagard, Immune Globulin Intravenous, Hepatitis B Immune Globulin, Privigen, Carimune, Gamunex-C, Sandoglobulin, Vivaglobin, Rhophylac, Synagis, MICRhoGAM, Immune Globulin Subcutaneous, Nabi-HB, WinRho SDF

Health Tip: Could Allergy Shots Help You?

Posted 21 Feb 2017 by Drugs.com

-- If you have allergies, regular shots (immunotherapy) are designed to make you less sensitive to allergens over time. The American Academy of Allergy, Asthma and Immunology says you may be a candidate for allergy shots if: Your symptoms are moderate-to-severe and your allergy season lasts a few months or more. You want to avoid long-term use of allergy medications. You can commit the time needed for getting regular allergy shots. You can afford the cost of allergy shots and related medical visits. Read more

Related support groups: Allergic Reactions, Allergies, Benadryl, Promethazine, Hydroxyzine, Zyrtec, Claritin, Loratadine, Allegra, Diphenhydramine, Phenergan, Vistaril, Allergic Rhinitis, Hay Fever, Cetirizine, Atarax, Cyproheptadine, Fexofenadine, Periactin, Chlorpheniramine

Immunotherapy Not a Quick Fix for Hay Fever

Posted 15 Feb 2017 by Drugs.com

TUESDAY, Feb. 14, 2017 – Immunotherapy – often in the form of allergy shots – can combat the runny nose, itchy eyes, congestion, sneezing and sinus pressure of persistent hay fever. But it can't be done in less than three years, British researchers report. Two years of immunotherapy was only as effective as a placebo, the study authors said. The key, the researchers added, seems to be a third year of treatment. "Immunotherapy for hay fever [allergic rhinitis] involves receiving a high dose of grass pollen vaccine either as a monthly injection or as a daily pill placed under the tongue," said lead researcher Dr. Stephen Durham. He is a professor of allergy and respiratory medicine at Imperial College London in England. About 15 percent of Americans suffer from diagnosed hay fever, and 30 percent report having symptoms of hay fever, which can negatively affect quality of life and ... Read more

Related support groups: Allergic Reactions, Allergies, Benadryl, Promethazine, Hydroxyzine, Zyrtec, Claritin, Loratadine, Allegra, Diphenhydramine, Phenergan, Vistaril, Allergic Rhinitis, Hay Fever, Cetirizine, Atarax, Cyproheptadine, Flonase, Fexofenadine, Periactin

Shire Announces FDA Approval of Cuvitru [immune globulin subcutaneous (human)] for Primary Immunodeficiency

Posted 16 Sep 2016 by Drugs.com

Lexington, Mass. – September 14, 2016 – Shire plc (LSE: SHP, NASDAQ: SHPG) announced that the United States Food and Drug Administration (FDA) has granted approval for Cuvitru [Immune Globulin Subcutaneous (Human), 20% Solution] in adult and pediatric patients two years of age and older. Cuvitru is a treatment for patients with primary immunodeficiency (PI), a group of more than 300 genetic disorders in which part of the body’s immune system is missing or functions improperly; it affects up to six million people worldwide. With the approval of Cuvitru, Shire now has the broadest portfolio of intravenous and subcutaneous immunoglobulin (IG) products, including the only once-a-month subcutaneous treatment option. Cuvitru is the only 20% subcutaneous IG treatment option without proline and with the ability to infuse up to 60 mL (12 grams) per site and 60 mL per hour, per site as tolerat ... Read more

Related support groups: Primary Immunodeficiency Syndrome, Immunodeficiency, Immune Globulin Subcutaneous, Cuvitru

Talecris Biotherapeutics Receives FDA Approval for Gamunex-C

Posted 17 Oct 2010 by Drugs.com

RESEARCH TRIANGLE PARK , N.C., Oct. 14 /PRNewswire-FirstCall/ – Talecris Biotherapeutics (Nasdaq: TLCR) announced today that the U.S. Food and Drug Administration (FDA) approved Gamunex-C (Immune Globulin Injection [Human], 10% Caprylate/Chromatography Purified) for subcutaneous administration in the treatment of primary immunodeficiency (PI). The newly approved Gamunex-C provides both the intravenous route of administration and a new subcutaneous route of administration. The intravenous delivery mode is approved to treat PI, chronic inflammatory demyelinating polyneuropathy (CIDP), and idiopathic thrombocytopenic purpura (ITP). The subcutaneous mode is approved to treat only PI. The difference between Gamunex and Gamunex-C is the labeling and packaging information. Gamunex-C labeling describes both the intravenous and subcutaneous routes of administration, whereas Gamunex labeling ... Read more

Related support groups: Primary Immunodeficiency Syndrome, Gamunex, Immune Globulin Subcutaneous

CSL Behring Receives FDA Approval of Hizentra, First 20 Percent Subcutaneous Immunoglobulin Therapy

Posted 10 Mar 2010 by Drugs.com

KING OF PRUSSIA, Pa.--(BUSINESS WIRE)--Mar 4, 2010 - CSL Behring announced today that the U.S. Food and Drug Administration (FDA) has granted marketing approval for Hizentra, Immune Globulin Subcutaneous (Human), 20% Liquid, for treating patients diagnosed with primary immunodeficiency (PI). A once weekly immunoglobulin (Ig) replacement therapy, Hizentra provides effective protection against infection by maintaining a steady and normal level of immunoglobulin in the body. Primary immunodeficiencies constitute a group of disorders, usually genetic, that cause a malfunction in all or part of the immune system, thereby rendering the patient unable to fight off infections caused by everyday germs. Hizentra is the first 20 percent subcutaneous immunoglobulin (SCIg) approved in the U.S. by the FDA. This high-concentration product is stabilized with L-proline, a naturally-occurring amino acid. ... Read more

Related support groups: Immune Globulin Subcutaneous

Ask a Question

Further Information

Related Condition Support Groups

Primary Immunodeficiency Syndrome

Related Drug Support Groups

Hizentra, Vivaglobin, Cuvitru

Immune Globulin Subcutaneous Patient Information at Drugs.com